プレフィルドシリンジ市場規模、シェア、動向、2031年までの世界予測

世界のプレフィルドシリンジ市場は、2026年の86億5000万米ドルから2031年には145億3000万米ドルに達するとMarketsandMarketsでは予測されており、予測期間中の年平均成長率は10.9%となる見込みです。

調査概要：

本レポートは、プレフィルドシリンジ市場を分析し、タイプ、素材、デザイン、用途、地域といった様々なセグメントに基づき、市場規模と将来の成長可能性を推定することを目的としています。また、主要企業の競合分析に加え、企業プロファイル、サービス内容、最近の動向、主要な市場戦略についても詳述しています。

本レポートを購入する理由

本レポートは、プレフィルドシリンジ市場全体および各サブセグメントの収益予測に関する最も正確な情報を提供することで、市場リーダーや新規参入企業を支援します。関係者は、本レポートを通じて競争環境を理解し、より的確な事業展開と適切な市場参入戦略の策定に向けた洞察を得ることができます。さらに、市場の動向を把握し、主要な市場推進要因、阻害要因、課題、機会に関する情報を提供することで、関係者の意思決定を支援します。

本レポートは、以下のポイントに関する洞察を提供します。

主要な推進要因（慢性疾患の増加、バイオ医薬品およびバイオシミラーの増加、技術革新）、阻害要因（製品リコールおよび厳格な政府規制）、機会（注射剤の自己投与への嗜好の高まりおよび規制当局による支援の強化）、課題（代替的な薬剤投与方法の存在および針刺し事故に伴う感染症）の分析

• 市場浸透度：世界のプレフィルドシリンジ市場における主要企業が提供する製品に関する詳細な情報が含まれています。レポートは、タイプ、材質、設計、用途、地域といった様々なセグメントを網羅しています。
• 製品改良／イノベーション：世界のプレフィルドシリンジ市場における新製品の発売状況および予測されるトレンドに関する包括的な詳細情報。
• 市場開発：タイプ、材質、設計、用途、地域別に、収益性の高い成長市場に関する徹底的な知識と分析。
• 市場の多様化：世界のプレフィルドシリンジ市場における新製品、拡大市場、最新の技術進歩、および投資に関する包括的な情報。
• 競合評価：世界のプレフィルドシリンジ市場における主要競合企業の市場シェア、成長戦略、製品ラインナップ、および生産能力を徹底的に評価。

Report Description

The global prefilled syringes market is projected to reach USD 14.53 billion by 2031 from USD 8.65 billion in 2026, at a CAGR of 10.9% during the forecast period.

“The increasing prevalence of chronic diseases, growing adoption of biologics and biosimilars, rising demand for self-administration, and advancements in biotechnology and pharmaceuticals contribute significantly to the growth of the prefilled syringes market.”

The prefilled syringes market has had strong growth due to a number of factors such as the rising incidence of chronic diseases like diabetes, rheumatoid arthritis, and cardiovascular disorders. Moreover, prefilled syringes make it easier to administer medications precisely and consistently to patients with chronic conditions, by providing ready-to-use doses that improve patient compliance and lower the possibility of dosage errors. Additionally, the growing trend of self-administration has also played a major role in the market’s growth. Prefilled syringes are preferred by patients due to their comfort and ease of use, as they eliminate the need for dose measurement, hence improving safety and lowering the danger of contamination.

“By type, the conventional prefilled syringes segment is expected to hold the largest market share in the prefilled syringes market.”

Based on type, the conventional prefilled syringes segment is expected to dominate the prefilled syringes market due to several factors. Their ready-to-use nature and pre-measured doses enhance convenience and safety by reducing preparation time and dosing errors. They lower contamination risks and needlestick injuries through advanced safety features. Prefilled syringes improve patient compliance, particularly for chronic conditions, by being user-friendly and encouraging adherence to treatment regimens. Their versatility in therapeutic applications, especially for biologics and chronic disease treatments, coupled with the growing prevalence of such conditions, further drive their market dominance.

“By material, the glass prefilled syringes segment is expected to hold the largest market share in the prefilled syringes market.”

Based on material, the glass prefilled syringes segment is expected to hold the largest market share in the prefilled syringes market. Their superior chemical inertness ensures drug stability and reduces the risk of interactions between the drug and the container, making them ideal for a wide range of pharmaceutical applications. Additionally, glass syringes offer high visibility, allowing for easy inspection of the drug for particulates and discoloration, which is critical for quality control and patient safety. As a result, pharmaceutical companies and healthcare providers prefer glass prefilled syringes for their reliability, safety, and efficiency in drug delivery.

“By design, the single-chamber prefilled syringes segment is expected to hold the largest market share in the prefilled syringes market.”

Based on design, the single-chamber prefilled syringes segment accounted for the largest market share of the prefilled syringes market due to their convenience, safety, and efficiency in drug administration. These syringes, which come pre-loaded with a single dose of medication, minimize the risk of dosing errors and contamination, enhancing patient safety. They streamline the injection process, making it quicker and easier for healthcare providers and patients, thereby improving compliance and treatment outcomes. Moreover, their widespread adoption in various therapeutic areas, particularly in chronic disease management and emergency care, further drives growth in the market.

“By application, the cancer segment is expected to hold the largest market share in the prefilled syringes market.”

By application, the cancer segment is expected to hold the largest market share due to the increasing prevalence of cancer globally and the rising need for advanced drug delivery systems. Prefilled syringes offer significant advantages for cancer treatment, including precise dosing, reduced risk of contamination, and enhanced patient safety and compliance. As cancer treatments often involve complex medication regimens requiring regular and accurate administration, the convenience and reliability of prefilled syringes become critical. Additionally, advancements in biologics and targeted therapies, which are frequently used in oncology, further drive the demand for prefilled syringes, making the cancer segment the dominant application area in this market.

“By region, North America is expected to hold the largest market share in the prefilled syringes market.”

North America is expected to hold the largest share of the prefilled syringes market during the forecast period due to several factors. These include a well-established healthcare infrastructure, high adoption rates of advanced medical technologies, and a significant focus on patient safety and convenience. Moreover, the region benefits from robust regulatory frameworks that encourage the adoption of prefilled syringes by ensuring stringent quality standards and safety measures. Additionally, the increasing incidence of chronic diseases requiring regular injections, coupled with rising healthcare expenditures, contribute to the growing demand for prefilled syringes in North America. The presence of major pharmaceutical companies and biotechnology firms further enhances market growth through extensive research and development activities aimed at improving drug delivery systems.

A breakdown of the primary participants (supply side) for the prefilled syringes market referred to for this report is provided below:

• By Company Type: Tier 1 (30%), Tier 2 (35%), and Tier 3 (35%)
• By Designation: C-level Executives (20%), Directors (35%), and Others (45%)
• By Region: North America (37%), Europe (34%), Asia Pacific (22%), Latin America (5%), Middle East & Africa (2%)

Prominent players in the prefilled syringes market are BD (US), Gerresheimer AG (Germany), SCHOTT (Germany), West Pharmaceutical Services, Inc. (US), AptarGroup Inc. (US), Nipro (Japan), Baxter (US), Owen Mumford Ltd. (UK), Weigao Medical International Co., Ltd. (China), Credence MedSystems, Inc. (US), Novartis AG (Switzerland), Stevanato Group (Italy), Polymed (India), MedXL (Canada), Sharps Technology, Inc. (US), Fresenius Kabi (US), DBM S.R.L. (Italy), Taisei Kako Co., Ltd. (Japan), Shandong Province Medicinal Glass Co., Ltd. (China), SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD. (Japan), J.O. PHARMA CO., LTD. (Japan), BMIKOREA (Korea), B. Braun SE ( Germany), and Al Shifa Medical Products Co. (Saudi Arabia).

Research Coverage:

The report analyzes the prefilled syringes market and aims at estimating the market size and future growth potential of this market based on various segments such as type, material, design, application, and region. The report also includes a competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall prefilled syringes market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

Analysis of key drivers (increasing chronic diseases, increasing biologics and biosimilars, and technological advancements), restraints (product recalls and stringent government regulations), opportunities (increasing preference for self-administration of injectables and increasing regulatory support), and challenges (presence of alternative drug delivery methods and infections associated with needlestick injuries)

• Market Penetration: It includes extensive information on products offered by the major players in the global prefilled syringes market. The report includes various segments in type, material, design, application, and region.
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global prefilled syringes market.
• Market Development: Thorough knowledge and analysis of the profitable rising markets by type, material, design, application, and region.
• Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global the prefilled syringes market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products, and capacities of the major competitors in the global prefilled syringes market.

Table of Contents

1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.3 STUDY SCOPE 28
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 28
1.3.2 INCLUSIONS & EXCLUSIONS 29
1.3.3 YEARS CONSIDERED 29
1.3.4 CURRENCY CONSIDERED 30
1.4 STAKEHOLDERS 30
1.5 SUMMARY OF CHANGES 31
2 EXECUTIVE SUMMARY 32
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 32
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & DEVELOPMENTS 34
2.3 DISRUPTIVE TRENDS SHAPING PREFILLED SYRINGES MARKET 34
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 35
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 36
3 PREMIUM INSIGHTS 37
3.1 PREFILLED SYRINGES MARKET OVERVIEW 37
3.2 PREFILLED SYRINGES MARKET, BY REGION, 2025 VS. 2030 38
3.3 ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY TYPE AND COUNTRY 39
3.4 PREFILLED SYRINGES MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 40
3.5 PREFILLED SYRINGES MARKET: DEVELOPED VS. EMERGING MARKETS 41
4 MARKET OVERVIEW 42
4.1 INTRODUCTION 42
4.2 MARKET DYNAMICS 42
4.2.1 DRIVERS 43
4.2.1.1 Increasing prevalence of chronic diseases 43
4.2.1.2 Growing adoption of self-injection devices 43
4.2.1.3 Increasing adoption of prefilled syringes in parenteral dosage forms 44
4.2.1.4 Increased use of biologics and vaccines 45
4.2.1.5 Technological advancements in prefilled syringes 45
4.2.2 RESTRAINTS 46
4.2.2.1 Stringent government regulations 46
4.2.2.2 Impact of product recalls 46

4.2.3 OPPORTUNITIES 47
4.2.3.1 Growing preference for unit-dose medication using prefilled syringes 47
4.2.3.2 Emerging markets with growing healthcare infrastructure 47
4.2.4 CHALLENGES 48
4.2.4.1 Alternative drug delivery methods 48
4.2.4.2 Infections associated with needlestick injuries 49
4.3 UNMET NEEDS & WHITE SPACES 49
4.3.1 UNMET NEEDS 49
4.3.2 WHITE SPACE OPPORTUNITIES 50
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 50
4.4.1 INTERCONNECTED MARKETS 50
4.4.2 CROSS-SECTOR OPPORTUNITIES 50
4.5 STRATEGIC MOVES BY TIER- 1/2/3 PLAYERS 51
5 INDUSTRY TRENDS 52
5.1 PORTER’S FIVE FORCES ANALYSIS 52
5.1.1 THREAT OF NEW ENTRANTS 53
5.1.2 THREAT OF SUBSTITUTES 53
5.1.3 BARGAINING POWER OF SUPPLIERS 53
5.1.4 BARGAINING POWER OF BUYERS 53
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 53
5.2 MACROECONOMIC OUTLOOK 54
5.2.1 GDP TRENDS AND FORECAST 54
5.2.2 TRENDS IN PREFILLED SYRINGES MARKET 56
5.3 VALUE CHAIN ANALYSIS 56
5.4 ECOSYSTEM ANALYSIS 57
5.5 SUPPLY CHAIN ANALYSIS 58
5.6 PRICING ANALYSIS 60
5.6.1 AVERAGE SELLING PRICE TREND OF PREFILLED SYRINGES, BY TYPE,
2022–2025 60
5.6.2 AVERAGE SELLING PRICE TREND OF CONVENTIONAL PREFILLED SYRINGES, BY REGION, 2022–2025 60
5.6.3 AVERAGE SELLING PRICE TREND OF SAFETY PREFILLED SYRINGES,
BY REGION, 2022–2025 61
5.6.4 AVERAGE SELLING PRICE TREND OF PREFILLED SYRINGES, BY KEY PLAYER, 2022–2025 61
5.7 TRADE ANALYSIS 62
5.7.1 IMPORT DATA FOR HS CODE 901831 62
5.7.2 EXPORT DATA FOR HS CODE 901831 62
5.8 KEY CONFERENCES & EVENTS, 2026 63
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 64
5.10 INVESTMENT & FUNDING SCENARIO 65

5.11 CASE STUDY ANALYSIS 65
5.11.1 ENVIRONMENTAL BENEFITS OF USING PREFILLED ‘EMERGENCY’ DRUGS 65
5.11.2 DEVELOPMENT OF NOVEL PHARMACEUTICAL DRUG MODALITIES REQUIRING FROZEN STORAGE AND TRANSPORTATION 66
5.12 IMPACT OF 2025 US TARIFF ON PREFILLED SYRINGES MARKET 67
5.12.1 INTRODUCTION 67
5.12.2 KEY TARIFF RATES 68
5.12.3 PRICE IMPACT ANALYSIS 69
5.12.3.1 Impact on country/region 69
5.12.3.1.1 US 69
5.12.3.1.2 Europe 69
5.12.3.1.3 Asia Pacific 69
5.12.4 IMPACT ON END-USE INDUSTRIES 70
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 71
6.1 KEY EMERGING TECHNOLOGIES 71
6.1.1 KEY TECHNOLOGIES 71
6.1.1.1 Integration Disinfection Unit (IDU) 71
6.1.2 COMPLEMENTARY TECHNOLOGIES 71
6.1.2.1 Cyclic Olefin Polymers (COP) and Cyclic Olefin Copolymers (COC) 71
6.1.3 ADJACENT TECHNOLOGIES 72
6.1.3.1 Integration with autoinjectors 72
6.2 TECHNOLOGY/PRODUCT ROADMAP 72
6.2.1 SHORT-TERM |RECENT TECHNOLOGIES| FOUNDATION & EARLY COMMERCIALIZATION 72
6.2.2 MID-TERM (2027–2030) | EXPANSION & STANDARDIZATION 73
6.2.3 LONG-TERM (2030–2035+) | MASS COMMERCIALIZATION & DISRUPTION 74
6.3 PATENT ANALYSIS 75
6.3.1 PATENT PUBLICATION TRENDS FOR PREFILLED SYRINGES 75
6.3.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 75
6.3.3 LIST OF PATENTS 77
6.4 IMPACT OF AI/GEN AI ON PREFILLED SYRINGES MARKET 78
6.4.1 TOP USE CASES AND MARKET POTENTIAL 79
6.4.2 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 79
6.4.3 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PREFILLED SYRINGES MARKET 80
6.5 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 80
6.5.1 STEVANATO GROUP: AI-DRIVEN VISUAL INSPECTION FOR PREFILLED SYRINGES 80
6.5.2 SCHOTT PHARMA: AI-ENABLED SMART GLASS & DEFECT PREDICTION 81
6.5.3 GERRESHEIMER: PREDICTIVE QUALITY CONTROL IN FILL-FINISH OPERATIONS 81
7 REGULATORY LANDSCAPE 82
7.1 REGIONAL REGULATIONS AND COMPLIANCE 82
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
7.1.2 INDUSTRY STANDARDS 84
7.2 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 85
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 86
8.1 DECISION-MAKING PROCESS 86
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 86
8.2.1 BUYING CRITERIA 87
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 87
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 88
9 PREFILLED SYRINGES MARKET, BY TYPE 89
9.1 INTRODUCTION 90
9.2 CONVENTIONAL PREFILLED SYRINGES 90
9.2.1 DISPOSABLE PREFILLED SYRINGES 93
9.2.1.1 Increasing focus on patient safety to drive market 93
9.2.2 REUSABLE PREFILLED SYRINGES 95
9.2.2.1 Cost-effectiveness and technological advancements to drive market 95
9.3 SAFETY PREFILLED SYRINGES 97
9.3.1 INTEGRATED SAFETY FEATURES TO BOOST ADOPTION 97
10 PREFILLED SYRINGES MARKET, BY DESIGN 99
10.1 INTRODUCTION 100
10.2 SINGLE-CHAMBER PREFILLED SYRINGES 100
10.2.1 CONVENIENCE, SAFETY, AND EFFICIENCY OF SINGLE-CHAMBER SYRINGES TO SUPPORT MARKET GROWTH 100
10.3 DUAL-CHAMBER PREFILLED SYRINGES 102
10.3.1 ABILITY TO MAINTAIN STABILITY, MINIMIZE DOSING ERRORS, AND MEET REGULATORY STANDARDS TO PROPEL MARKET GROWTH 102
10.4 CUSTOMIZED PREFILLED SYRINGES 104
10.4.1 EASY-TO-READ DOSAGE INDICATORS AND SAFETY MECHANISMS TO BOOST ADOPTION 104
11 PREFILLED SYRINGES MARKET, BY MATERIAL 106
11.1 INTRODUCTION 107
11.2 GLASS PREFILLED SYRINGES 107
11.2.1 ABILITY OF GLASS PREFILLED SYRINGES TO OFFER SUPERIOR BARRIER PROPERTIES TO BOOST MARKET GROWTH 107
11.3 PLASTIC PREFILLED SYRINGES 109
11.3.1 IMPROVED SAFETY, COST-EFFECTIVENESS, VERSATILITY, AND CONVENIENCE TO SUPPORT ADOPTION 109
12 PREFILLED SYRINGES MARKET, BY APPLICATION 111
12.1 INTRODUCTION 112
12.2 DIABETES 112
12.2.1 INCREASING PREVALENCE OF DIABETES TO FAVOR MARKET GROWTH 112
12.3 RHEUMATOID ARTHRITIS 114
12.3.1 RISING DEMAND FOR EFFECTIVE AND CONVENIENT TREATMENT OPTIONS TO AID MARKET GROWTH 114
12.4 ANAPHYLAXIS 116
12.4.1 CONVENIENCE OF PREFILLED SYRINGES TO ADMINISTER MEDICATION QUICKLY TO BOOST ADOPTION 116
12.5 CANCER 118
12.5.1 RISING GLOBAL CANCER RATES TO SPUR MARKET GROWTH 118
12.6 THROMBOSIS 120
12.6.1 MINIMIZED RISK OF CONTAMINATION AND INFECTION ASSOCIATED WITH PREFILLED SYRINGES TO AUGMENT MARKET DEMAND 120
12.7 OPHTHALMOLOGY 121
12.7.1 FEWER SIDE EFFECTS ASSOCIATED WITH PREFILLED SYRINGES COMPARED TO TOPICAL MEDICATIONS TO SUPPORT GROWTH 121
12.8 OTHER APPLICATIONS 123
13 PREFILLED SYRINGES MARKET, BY REGION 124
13.1 INTRODUCTION 125
13.2 NORTH AMERICA 126
13.2.1 US 130
13.2.1.1 US to dominate North American prefilled syringes market during forecast period 130
13.2.2 CANADA 132
13.2.2.1 Rising incidence of chronic diseases to propel market growth 132
13.3 EUROPE 135
13.3.1 GERMANY 138
13.3.1.1 High investment in healthcare R&D to foster innovation in drug delivery technologies 138
13.3.2 UK 140
13.3.2.1 Rising number of patients with cardiovascular diseases and diabetes patients to fuel market growth 140
13.3.3 FRANCE 143
13.3.3.1 Increasing incidence of needlestick injuries and growing trend of self-administration to drive market growth 143
13.3.4 SPAIN 145
13.3.4.1 Increase in biologics production to support market growth 145
13.3.5 ITALY 148
13.3.5.1 Growing focus of pharmaceutical and medical device companies on high-quality manufacturing standards to drive market 148
13.3.6 REST OF EUROPE 150
13.4 ASIA PACIFIC 152
13.4.1 JAPAN 156
13.4.1.1 Increase in geriatric population to augment market growth 156
13.4.2 CHINA 158
13.4.2.1 Large diabetic population to attract pharmaceutical and drug delivery device manufacturers to Chinese market 158
13.4.3 INDIA 161
13.4.3.1 High number of cancer and diabetes cases to fuel market growth 161
13.4.4 AUSTRALIA 163
13.4.4.1 Growing healthcare expenditure and rising focus on chronic disease management to aid market growth 163
13.4.5 SOUTH KOREA 166
13.4.5.1 Well-developed healthcare sector and presence of major pharmaceutical manufacturers to drive market 166
13.4.6 REST OF ASIA PACIFIC 168
13.5 LATIN AMERICA 170
13.5.1 BRAZIL 173
13.5.1.1 Increasing prevalence of obesity and rising use of generic medicines to aid market growth 173
13.5.2 MEXICO 176
13.5.2.1 Rising Healthcare Investment and Pharmaceutical Expansion to propel market growth 176
13.5.3 ARGENTINA 178
13.5.3.1 Increasing geriatric population with chronic diseases to fuel demand for prefilled syringes 178
13.5.4 REST OF LATIN AMERICA 181
13.6 MIDDLE EAST & AFRICA 183
13.6.1 RISING CHRONIC DISEASE BURDEN AND HEALTHCARE INVESTMENTS TO BOOST MARKET 183
13.7 GCC COUNTRIES 186
13.7.1 INCREASING HEALTHCARE EXPENDITURE TO DRIVE MARKET 186
14 COMPETITIVE LANDSCAPE 189
14.1 INTRODUCTION 189
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 189
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN PREFILLED SYRINGES MARKET 190
14.3 REVENUE ANALYSIS, 2020–2024 191
14.4 MARKET SHARE ANALYSIS, 2025 192
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 194
14.5.1 STARS 194
14.5.2 EMERGING LEADERS 194
14.5.3 PERVASIVE PLAYERS 194
14.5.4 PARTICIPANTS 194
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 196
14.5.5.1 Company footprint 196
14.5.5.2 Region footprint 197
14.5.5.3 Type footprint 198
14.5.5.4 Material footprint 199
14.5.5.5 Design footprint 200
14.5.5.6 Application footprint 201
14.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024 202
14.6.1 PROGRESSIVE COMPANIES 202
14.6.2 RESPONSIVE COMPANIES 202
14.6.3 DYNAMIC COMPANIES 203
14.6.4 STARTING BLOCKS 203
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 204
14.6.5.1 Detailed list of key Startups/SMEs 204
14.6.5.2 Competitive benchmarking of Startups/SMEs 204
14.7 BRAND/PRODUCT COMPARISON 205
14.8 COMPANY VALUATION & FINANCIAL METRICS 206
14.8.1 FINANCIAL METRICS 206
14.8.2 COMPANY VALUATION 206
14.9 R&D EXPENDITURE 207
14.10 COMPETITIVE SCENARIO 207
14.10.1 PRODUCT LAUNCHES AND APPROVALS 207
14.10.2 DEALS 209
14.10.3 EXPANSIONS 210
15 COMPANY PROFILES 212
15.1 KEY PLAYERS 212
15.1.1 BECTON, DICKINSON AND COMPANY (BD) 212
15.1.1.1 Business overview 212
15.1.1.2 Products offered 213
15.1.1.3 Recent developments 215
15.1.1.3.1 Product launches 215
15.1.1.3.2 Deals 215
15.1.1.3.3 Expansions 217
15.1.1.4 MnM view 217
15.1.1.4.1 Right to win 217
15.1.1.4.2 Strategic choices 217
15.1.1.4.3 Weaknesses & competitive threats 218

15.1.2 GERRESHEIMER AG 219
15.1.2.1 Business overview 219
15.1.2.2 Products offered 220
15.1.2.3 Recent developments 221
15.1.2.3.1 Product launches 221
15.1.2.3.2 Deals 221
15.1.2.3.3 Expansions 222
15.1.2.4 MnM view 224
15.1.2.4.1 Right to win 224
15.1.2.4.2 Strategic choices 224
15.1.2.4.3 Weaknesses & competitive threats 224
15.1.3 SCHOTT 225
15.1.3.1 Business overview 225
15.1.3.2 Products offered 226
15.1.3.3 Recent developments 227
15.1.3.3.1 Product launches 227
15.1.3.3.2 Expansions 227
15.1.3.4 MnM view 228
15.1.3.4.1 Right to win 228
15.1.3.4.2 Strategic choices 228
15.1.3.4.3 Weaknesses & competitive threats 228
15.1.4 WEST PHARMACEUTICAL SERVICES, INC. 229
15.1.4.1 Business overview 229
15.1.4.2 Products offered 230
15.1.4.3 Recent developments 231
15.1.4.3.1 Product launches 231
15.1.4.3.2 Deals 231
15.1.4.3.3 Expansions 232
15.1.4.4 MnM view 234
15.1.4.4.1 Right to win 234
15.1.4.4.2 Strategic choices 234
15.1.4.4.3 Weaknesses & competitive threats 234
15.1.5 APTARGROUP, INC. 235
15.1.5.1 Business overview 235
15.1.5.2 Products offered 236
15.1.5.3 Recent developments 237
15.1.5.3.1 Deals 237
15.1.5.3.2 Expansions 237
15.1.5.4 MnM view 238
15.1.5.4.1 Right to win 238
15.1.5.4.2 Strategic choices 238
15.1.5.4.3 Weaknesses & competitive threats 238
15.1.6 NIPRO 239
15.1.6.1 Business overview 239
15.1.6.2 Products offered 240
15.1.6.3 Recent developments 241
15.1.6.3.1 Product launches 241
15.1.6.3.2 Expansions 242
15.1.7 BAXTER (SIMTRA BIOPHARMA SOLUTIONS) 243
15.1.7.1 Business overview 243
15.1.7.2 Products offered 244
15.1.7.3 Recent developments 245
15.1.7.3.1 Product launches 245
15.1.7.3.2 Deals 245
15.1.7.3.3 Expansions 246
15.1.8 OWEN MUMFORD LTD. 247
15.1.8.1 Business overview 247
15.1.8.2 Products offered 247
15.1.8.3 Recent developments 248
15.1.8.3.1 Product launches 248
15.1.8.3.2 Deals 248
15.1.9 WEIGAO MEDICAL INTERNATIONAL CO., LTD. 249
15.1.9.1 Business overview 249
15.1.9.2 Products offered 250
15.1.10 CREDENCE MEDSYSTEMS, INC. 251
15.1.10.1 Business overview 251
15.1.10.2 Products offered 251
15.1.11 NOVARTIS AG 252
15.1.11.1 Business overview 252
15.1.11.2 Products offered 253
15.1.11.3 Recent developments 254
15.1.11.3.1 Deals 254
15.1.12 STEVANATO GROUP 255
15.1.12.1 Business overview 255
15.1.12.2 Products offered 256
15.1.12.3 Recent developments 257
15.1.12.3.1 Product launches 257
15.1.12.3.2 Deals 257
15.1.12.3.3 Expansions 258
15.1.13 POLYMEDICURE 260
15.1.13.1 Business overview 260
15.1.13.2 Products offered 260

15.1.14 AMSINO INTERNATIONAL, INC. 261
15.1.14.1 Business overview 261
15.1.14.2 Products offered 261
15.1.14.3 Recent developments 262
15.1.14.3.1 Deals 262
15.1.15 SHARPS TECHNOLOGY, INC. 263
15.1.15.1 Business overview 263
15.1.15.2 Products offered 263
15.2 OTHER PLAYERS 264
15.2.1 FRESENIUS KABI USA 264
15.2.2 MEDEFIL, INC. 265
15.2.3 D.B.M. S.R.L. 266
15.2.4 TAISEI KAKO CO., LTD. 267
15.2.5 SHANDONG PROVINCE MEDICINAL GLASS CO., LTD. 268
15.2.6 SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD. 269
15.2.7 J.O. PHARMA CO., LTD. (OTSUKA HOLDINGS CO., LTD.) 270
15.2.8 BMI KOREA 271
15.2.9 B. BRAUN SE 272
15.2.10 AL SHIFA MEDICAL PRODUCTS CO. 273
16 RESEARCH METHODOLOGY 274
16.1 RESEARCH DATA 274
16.1.1 SECONDARY DATA 275
16.1.1.1 Key data from secondary sources 275
16.1.2 PRIMARY DATA 276
16.1.2.1 Key primary sources 276
16.1.2.2 Key objectives of primary research 276
16.1.2.3 Key data from primary sources 277
16.1.2.4 Key industry insights 278
16.2 MARKET SIZE ESTIMATION 280
16.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 280
16.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 281
16.2.3 TOP-DOWN APPROACH 282
16.3 DATA TRIANGULATION 285
16.4 MARKET SHARE ESTIMATION 286
16.5 STUDY ASSUMPTIONS 286
16.6 RESEARCH LIMITATIONS 287
16.6.1 METHODOLOGY-RELATED LIMITATIONS 287
16.7 RISK ASSESSMENT 287

17 APPENDIX 288
17.1 DISCUSSION GUIDE 288
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 293
17.3 RELATED REPORTS 295
17.4 AUTHOR DETAILS 296

LIST OF TABLES

TABLE 1 PREFILLED SYRINGES MARKET: INCLUSIONS & EXCLUSIONS 29
TABLE 2 STANDARD CURRENCY CONVERSION RATES 30
TABLE 3 UNMET NEEDS IN PREFILLED SYRINGES MARKET 49
TABLE 4 IMPACT OF PORTER’S FIVE FORCES ON PREFILLED SYRINGES MARKET 52
TABLE 5 GDP PERCENTAGE CHANGE, BY KEY COUNTRY, 2021–2030 54
TABLE 6 ROLE OF COMPANIES IN PREFILLED SYRINGES MARKET ECOSYSTEM ANALYSIS 58
TABLE 7 AVERAGE SELLING PRICE TREND OF PREFILLED SYRINGES, BY TYPE,
2022–2025 (USD) 60
TABLE 8 AVERAGE SELLING PRICE OF CONVENTIONAL PREFILLED SYRINGES, BY REGION, 2022–2025 (USD) 60
TABLE 9 AVERAGE SELLING PRICE OF SAFETY PREFILLED SYRINGES, BY REGION,
2022–2025 (USD) 61
TABLE 10 AVERAGE SELLING PRICE TREND OF PREFILLED SYRINGES, BY KEY PLAYER, 2022–2025 (USD) 61
TABLE 11 IMPORT DATA FOR PREFILLED SYRINGES (HS CODE 901831), BY COUNTRY, 2020–2024 (USD THOUSAND) 62
TABLE 12 EXPORT DATA FOR PREFILLED SYRINGES (HS CODE 901831), BY COUNTRY, 2020–2024 (USD THOUSAND) 62
TABLE 13 PREFILLED SYRINGES MARKET: KEY CONFERENCES & EVENTS,
JANUARY 2026–DECEMBER 2026 63
TABLE 14 CASE STUDY 1: ENVIRONMENTAL BENEFITS OF USING PREFILLED ‘EMERGENCY’ DRUGS 65
TABLE 15 CASE STUDY 2: DEVELOPMENT OF NOVEL PHARMACEUTICAL DRUG MODALITIES REQUIRING FROZEN STORAGE AND TRANSPORTATION 66
TABLE 16 US-ADJUSTED RECIPROCAL TARIFF RATES 68
TABLE 17 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR PREFILLED SYRINGES 68
TABLE 18 LIST OF MAJOR PATENTS IN PREFILLED SYRINGES MARKET (2022−2025) 77
TABLE 19 TOP USE CASES AND MARKET POTENTIAL 79
TABLE 20 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 79
TABLE 21 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 22 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 23 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 24 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 25 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84
TABLE 26 GLOBAL STANDARDS IN PREFILLED SYRINGES MARKET 84
TABLE 27 CERTIFICATIONS, LABELING, AND ECO-STANDARDS IN PREFILLED SYRINGES MARKET 85
TABLE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PREFILLED SYRINGES 86
TABLE 29 KEY BUYING CRITERIA FOR PREFILLED SYRINGES 87
TABLE 30 UNMET NEEDS FROM END-USE INDUSTRIES IN PREFILLED SYRINGES MARKET 88
TABLE 31 PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 90
TABLE 32 CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 91
TABLE 33 CONVENTIONAL PREFILLED SYRINGES MARKET, BY REGION,
2024–2031 (MILLION UNITS) 91
TABLE 34 CONVENTIONAL PREFILLED SYRINGES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 92
TABLE 35 DISPOSABLE PREFILLED SYRINGES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 94
TABLE 36 REUSABLE PREFILLED SYRINGES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 96
TABLE 37 SAFETY PREFILLED SYRINGES MARKET, BY REGION, 2024–2031 (MILLION UNITS) 97
TABLE 38 SAFETY PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 98
TABLE 39 PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 100
TABLE 40 SINGLE-CHAMBER PREFILLED SYRINGES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 101
TABLE 41 DUAL-CHAMBER PREFILLED SYRINGES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 103
TABLE 42 CUSTOMIZED PREFILLED SYRINGES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 105
TABLE 43 PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 107
TABLE 44 GLASS PREFILLED SYRINGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 108
TABLE 45 PLASTIC PREFILLED SYRINGES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 110
TABLE 46 PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 112
TABLE 47 PREFILLED SYRINGES MARKET FOR DIABETES, BY COUNTRY,
2024–2031 (USD MILLION) 113
TABLE 48 PREFILLED SYRINGES MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 49 PREFILLED SYRINGES MARKET FOR ANAPHYLAXIS, BY COUNTRY,
2024–2031 (USD MILLION) 117
TABLE 50 PREFILLED SYRINGES MARKET FOR CANCER, BY COUNTRY,
2024–2031 (USD MILLION) 119
TABLE 51 PREFILLED SYRINGES MARKET FOR THROMBOSIS, BY COUNTRY,
2024–2031 (USD MILLION) 121
TABLE 52 PREFILLED SYRINGES MARKET FOR OPHTHALMOLOGY, BY COUNTRY,
2024–2031 (USD MILLION) 122
TABLE 53 PREFILLED SYRINGES MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 123
TABLE 54 PREFILLED SYRINGES MARKET, BY REGION, 2024–2031 (USD MILLION) 126
TABLE 55 NORTH AMERICA: PREFILLED SYRINGES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 128
TABLE 56 NORTH AMERICA: PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 128
TABLE 57 NORTH AMERICA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 128
TABLE 58 NORTH AMERICA: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 129
TABLE 59 NORTH AMERICA: PREFILLED SYRINGES MARKET, BY DESIGN,
2024–2031 (USD MILLION) 129
TABLE 60 NORTH AMERICA: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 130
TABLE 61 US: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 131
TABLE 62 US: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 131
TABLE 63 US: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 131
TABLE 64 US: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 132
TABLE 65 US: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 132
TABLE 66 CANADA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 133
TABLE 67 CANADA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 133
TABLE 68 CANADA: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 134
TABLE 69 CANADA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 134
TABLE 70 CANADA: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 135
TABLE 71 EUROPE: PREFILLED SYRINGES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 136
TABLE 72 EUROPE: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 136
TABLE 73 EUROPE: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 136
TABLE 74 EUROPE: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 137
TABLE 75 EUROPE: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 137
TABLE 76 EUROPE: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 138
TABLE 77 GERMANY: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 139
TABLE 78 GERMANY: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 139
TABLE 79 GERMANY: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 139
TABLE 80 GERMANY: PREFILLED SYRINGES MARKET, BY DESIGN,
2024–2031 (USD MILLION) 140
TABLE 81 GERMANY: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 140
TABLE 82 UK: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 141
TABLE 83 UK: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 141
TABLE 84 UK: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 142
TABLE 85 UK: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 142
TABLE 86 UK: PREFILLED SYRINGES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 143
TABLE 87 FRANCE: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 144
TABLE 88 FRANCE: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 144
TABLE 89 FRANCE: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 144
TABLE 90 FRANCE: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 145
TABLE 91 FRANCE: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 145
TABLE 92 SPAIN: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 146
TABLE 93 SPAIN: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 146
TABLE 94 SPAIN: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 146
TABLE 95 SPAIN: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 147
TABLE 96 SPAIN: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 147
TABLE 97 ITALY: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 148
TABLE 98 ITALY: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 148
TABLE 99 ITALY: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 149
TABLE 100 ITALY: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 149
TABLE 101 ITALY: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 150
TABLE 102 REST OF EUROPE: PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 150
TABLE 103 REST OF EUROPE: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 151
TABLE 104 REST OF EUROPE: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 151
TABLE 105 REST OF EUROPE: PREFILLED SYRINGES MARKET, BY DESIGN,
2024–2031 (USD MILLION) 151
TABLE 106 REST OF EUROPE: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 152
TABLE 107 ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 153
TABLE 108 ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 154
TABLE 109 ASIA PACIFIC: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 154
TABLE 110 ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 154
TABLE 111 ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY DESIGN,
2024–2031 (USD MILLION) 155
TABLE 112 ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 155
TABLE 113 JAPAN: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 156
TABLE 114 JAPAN: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 156
TABLE 115 JAPAN: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 157
TABLE 116 JAPAN: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 157
TABLE 117 JAPAN: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 158
TABLE 118 CHINA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 159
TABLE 119 CHINA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 159
TABLE 120 CHINA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 159
TABLE 121 CHINA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 160
TABLE 122 CHINA: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 160
TABLE 123 INDIA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 161
TABLE 124 INDIA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 162
TABLE 125 INDIA: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 162
TABLE 126 INDIA: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 162
TABLE 127 INDIA: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 163
TABLE 128 AUSTRALIA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 164
TABLE 129 AUSTRALIA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 164
TABLE 130 AUSTRALIA: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 164
TABLE 131 AUSTRALIA: PREFILLED SYRINGES MARKET, BY DESIGN,
2024–2031 (USD MILLION) 165
TABLE 132 AUSTRALIA: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 165
TABLE 133 SOUTH KOREA: PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 166
TABLE 134 SOUTH KOREA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 167
TABLE 135 SOUTH KOREA: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 167
TABLE 136 SOUTH KOREA: PREFILLED SYRINGES MARKET, BY DESIGN,
2024–2031 (USD MILLION) 167
TABLE 137 SOUTH KOREA: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 168
TABLE 138 REST OF ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 168
TABLE 139 REST OF ASIA PACIFIC: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 169
TABLE 140 REST OF ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 169
TABLE 141 REST OF ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY DESIGN,
2024–2031 (USD MILLION) 169
TABLE 142 REST OF ASIA PACIFIC: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 170
TABLE 143 LATIN AMERICA: PREFILLED SYRINGES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 171
TABLE 144 LATIN AMERICA: PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 171
TABLE 145 LATIN AMERICA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 171
TABLE 146 LATIN AMERICA: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 172
TABLE 147 LATIN AMERICA: PREFILLED SYRINGES MARKET, BY DESIGN,
2024–2031 (USD MILLION) 172

TABLE 148 LATIN AMERICA: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 173
TABLE 149 BRAZIL: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 174
TABLE 150 BRAZIL: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 174
TABLE 151 BRAZIL: PREFILLED SYRINGES MARKET, BY MATERIAL, 2024–2031 (USD MILLION) 174
TABLE 152 BRAZIL: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 175
TABLE 153 BRAZIL: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 175
TABLE 154 MEXICO: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 176
TABLE 155 MEXICO: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 176
TABLE 156 MEXICO: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 177
TABLE 157 MEXICO: PREFILLED SYRINGES MARKET, BY DESIGN, 2024–2031 (USD MILLION) 177
TABLE 158 MEXICO: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 178
TABLE 159 ARGENTINA: PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 179
TABLE 160 ARGENTINA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 179
TABLE 161 ARGENTINA: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 179
TABLE 162 ARGENTINA: PREFILLED SYRINGES MARKET, BY DESIGN,
2024–2031 (USD MILLION) 180
TABLE 163 ARGENTINA: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 180
TABLE 164 REST OF LATIN AMERICA: PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 181
TABLE 165 REST OF LATIN AMERICA: CONVENTIONAL PREFILLED SYRINGES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 181
TABLE 166 REST OF LATIN AMERICA: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 182
TABLE 167 REST OF LATIN AMERICA: PREFILLED SYRINGES MARKET, BY DESIGN,
2024–2031 (USD MILLION) 182
TABLE 168 REST OF LATIN AMERICA: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 183
TABLE 169 MIDDLE EAST & AFRICA: PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 184
TABLE 170 MIDDLE EAST & AFRICA: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE, 2024–2031 (USD MILLION) 184
TABLE 171 MIDDLE EAST & AFRICA: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 184
TABLE 172 MIDDLE EAST & AFRICA: PREFILLED SYRINGES MARKET, BY DESIGN,
2024–2031 (USD MILLION) 185
TABLE 173 MIDDLE EAST & AFRICA: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 185

TABLE 174 GCC COUNTRIES: PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 186
TABLE 175 GCC COUNTRIES: CONVENTIONAL PREFILLED SYRINGES MARKET, BY TYPE,
2024–2031 (USD MILLION) 186
TABLE 176 GCC COUNTRIES: PREFILLED SYRINGES MARKET, BY MATERIAL,
2024–2031 (USD MILLION) 187
TABLE 177 GCC COUNTRIES: PREFILLED SYRINGES MARKET, BY DESIGN,
2024–2031 (USD MILLION) 187
TABLE 178 GCC COUNTRIES: PREFILLED SYRINGES MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 188
TABLE 179 OVERVIEW OF STRATEGIES ADOPTED BY KEY COMPANIES IN PREFILLED
SYRINGES MARKET 190
TABLE 180 PREFILLED SYRINGES MARKET: DEGREE OF COMPETITION 193
TABLE 181 PREFILLED SYRINGES MARKET: REGION FOOTPRINT 197
TABLE 182 PREFILLED SYRINGES MARKET: TYPE FOOTPRINT 198
TABLE 183 PREFILLED SYRINGES MARKET: MATERIAL FOOTPRINT 199
TABLE 184 PREFILLED SYRINGES MARKET: DESIGN FOOTPRINT 200
TABLE 185 PREFILLED SYRINGES MARKET: APPLICATION FOOTPRINT 201
TABLE 186 PREFILLED SYRINGES MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 204
TABLE 187 PREFILLED SYRINGES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/ SME PLAYERS, BY TYPE AND REGION 204
TABLE 188 PREFILLED SYRINGES MARKET: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–NOVEMBER 2025 207
TABLE 189 PREFILLED SYRINGES MARKET: DEALS, JANUARY 2022–NOVEMBER 2025 209
TABLE 190 PREFILLED SYRINGES MARKET: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 210
TABLE 191 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 212
TABLE 192 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 213
TABLE 193 BECTON, DICKINSON AND COMPANY (BD): PRODUCT LAUNCHES,
JANUARY 2022–FEBRUARY 2026 215
TABLE 194 BECTON, DICKINSON AND COMPANY (BD): DEALS,
JANUARY 2022–FEBRUARY 2026 215
TABLE 195 BECTON, DICKINSON AND COMPANY (BD): EXPANSIONS,
JANUARY 2022–FEBRUARY 2026 217
TABLE 196 GERRESHEIMER AG: COMPANY OVERVIEW 219
TABLE 197 GERRESHEIMER AG: PRODUCTS OFFERED 220
TABLE 198 GERRESHEIMER AG: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 221
TABLE 199 GERRESHEIMER AG: DEALS, JANUARY 2022–FEBRUARY 2026 221
TABLE 200 GERRESHEIMER AG: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 222
TABLE 201 SCHOTT: COMPANY OVERVIEW 225
TABLE 202 SCHOTT: PRODUCTS OFFERED 226
TABLE 203 SCHOTT: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 227
TABLE 204 SCHOTT: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 227
TABLE 205 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW 229
TABLE 206 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCTS OFFERED 230

TABLE 207 WEST PHARMACEUTICAL SERVICES, INC.: PRODUCT LAUNCHES,
JANUARY 2022–FEBRUARY 2026 231
TABLE 208 WEST PHARMACEUTICAL SERVICES, INC.: DEALS,
JANUARY 2022–FEBRUARY 2026 231
TABLE 209 WEST PHARMACEUTICAL SERVICES, INC.: EXPANSIONS,
JANUARY 2022–FEBRUARY 2026 232
TABLE 210 APTARGROUP, INC.: COMPANY OVERVIEW 235
TABLE 211 APTARGROUP, INC.: PRODUCTS OFFERED 236
TABLE 212 APTARGROUP, INC.: DEALS, JANUARY 2022–FEBRUARY 2026 237
TABLE 213 APTARGROUP, INC.: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 237
TABLE 214 NIPRO: COMPANY OVERVIEW 239
TABLE 215 NIPRO: PRODUCTS OFFERED 240
TABLE 216 NIPRO: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 241
TABLE 217 NIPRO: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 242
TABLE 218 BAXTER (SIMTRA BIOPHARMA SOLUTIONS): COMPANY OVERVIEW 243
TABLE 219 BAXTER (SIMTRA BIOPHARMA SOLUTIONS): PRODUCTS OFFERED 244
TABLE 220 BAXTER (SIMTRA BIOPHARMA SOLUTIONS): PRODUCT LAUNCHES,
JANUARY 2022–FEBRUARY 2026 245
TABLE 221 BAXTER (SIMTRA BIOPHARMA SOLUTIONS): DEALS,
JANUARY 2022–FEBRUARY 2026 245
TABLE 222 BAXTER (SIMTRA BIOPHARMA SOLUTIONS): EXPANSIONS,
JANUARY 2022–FEBRUARY 2026 246
TABLE 223 OWEN MUMFORD LTD.: COMPANY OVERVIEW 247
TABLE 224 OWEN MUMFORD LTD.: PRODUCTS OFFERED 247
TABLE 225 OWEN MUMFORD LTD.: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 248
TABLE 226 OWEN MUMFORD LTD.: DEALS, JANUARY 2022–FEBRUARY 2026 248
TABLE 227 WEIGAO MEDICAL INTERNATIONAL CO., LTD.: COMPANY OVERVIEW 249
TABLE 228 WEIGAO MEDICAL INTERNATIONAL CO., LTD.: PRODUCTS OFFERED 250
TABLE 229 CREDENCE MEDSYSTEMS, INC.: COMPANY OVERVIEW 251
TABLE 230 CREDENCE MEDSYSTEMS, INC.: PRODUCTS OFFERED 251
TABLE 231 NOVARTIS AG: COMPANY OVERVIEW 252
TABLE 232 NOVARTIS AG: PRODUCTS OFFERED 253
TABLE 233 NOVARTIS AG: DEALS, JANUARY 2022–FEBRUARY 2026 254
TABLE 234 STEVANATO GROUP: COMPANY OVERVIEW 255
TABLE 235 STEVANATO GROUP: PRODUCTS OFFERED 256
TABLE 236 STEVANATO GROUP: PRODUCT LAUNCHES, JANUARY 2022–FEBRUARY 2026 257
TABLE 237 STEVANATO GROUP: DEALS, JANUARY 2022–FEBRUARY 2026 257
TABLE 238 STEVANATO GROUP: EXPANSIONS, JANUARY 2022–FEBRUARY 2026 258
TABLE 239 POLYMEDICURE: COMPANY OVERVIEW 260
TABLE 240 POLYMEDICURE: PRODUCTS OFFERED 260
TABLE 241 AMSINO INTERNATIONAL, INC.: COMPANY OVERVIEW 261
TABLE 242 AMSINO INTERNATIONAL, INC.: PRODUCTS OFFERED 261

TABLE 243 AMSINO INTERNATIONAL, INC.: DEALS, JANUARY 2022–FEBRUARY 2026 262
TABLE 244 SHARPS TECHNOLOGY, INC.: COMPANY OVERVIEW 263
TABLE 245 SHARPS TECHNOLOGY, INC.: PRODUCTS OFFERED 263
TABLE 246 FRESENIUS KABI USA: COMPANY OVERVIEW 264
TABLE 247 MEDEFIL, INC.: COMPANY OVERVIEW 265
TABLE 248 D.B.M. S.R.L.: COMPANY OVERVIEW 266
TABLE 249 TAISEI KAKO CO., LTD.: COMPANY OVERVIEW 267
TABLE 250 SHANDONG PROVINCE MEDICINAL GLASS CO., LTD.: COMPANY OVERVIEW 268
TABLE 251 SHIN YAN SHENO PRECISION INDUSTRIAL CO., LTD.: COMPANY OVERVIEW 269
TABLE 252 J.O. PHARMA CO., LTD. (OTSUKA HOLDINGS CO., LTD.): COMPANY OVERVIEW 270
TABLE 253 BMI KOREA: COMPANY OVERVIEW 271
TABLE 254 B. BRAUN SE: COMPANY OVERVIEW 272
TABLE 255 AL SHIFA MEDICAL PRODUCTS CO.: COMPANY OVERVIEW 273
TABLE 256 PREFILLED SYRINGES MARKET: STUDY ASUSMPTIONS 286
TABLE 257 PREFILLED SYRINGES MARKET: RISK ASSESSMENT 287

LIST OF FIGURES

FIGURE 1 PREFILLED SYRINGES MARKET SEGMENTATION & REGIONAL SCOPE 28
FIGURE 2 PREFILLED SYRINGES MARKET: YEARS CONSIDERED 29
FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS 32
FIGURE 4 PREFILELD SYRINGES MARKET SIZE, 2026–2031 (USD MILLION) 33
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PREFILLED SYRINGES MARKET 34
FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF PREFILLED SYRINGES MARKET 34
FIGURE 7 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN PREFILLED SYRINGES MARKET, BY TYPE, MATERIAL, DESIGN, AND REGION (2025) 35
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 36
FIGURE 9 INCREASING HEALTHCARE EXPENDITURE AND RISING PREVALENCE OF CHRONIC DISEASES AMONG OLDER POPULATION TO DRIVE MARKET 37
FIGURE 10 NORTH AMERICA TO DOMINATE MARKET SHARE THROUGHOUT FORECAST PERIOD 38
FIGURE 11 JAPAN AND CONVENTIONAL PREFILLED SYRINGES ACCOUNTED FOR LARGEST
ASIA PACIFIC PREFILLED SYRINGES MARKET SHARE IN 2025 39
FIGURE 12 CHINA TO GROW AT HIGHEST CAGR DURING STUDY PERIOD 40
FIGURE 13 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES FROM
2026 TO 2031 41
FIGURE 14 PREFILLED SYRINGES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 42
FIGURE 15 PREFILLED SYRINGES MARKET: PORTER’S FIVE FORCES ANALYSIS 52
FIGURE 16 PREFILLED SYRINGES MARKET: VALUE CHAIN ANALYSIS 57
FIGURE 17 PREFILLED SYRINGES MARKET: SUPPLY CHAIN ANALYSIS 59
FIGURE 18 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS IN PREFILLED SYRINGES MARKET 64
FIGURE 19 INVESTMENT/VENTURE CAPITAL SCENARIO IN PREFILLED SYRINGES MARKET, 2021–2024 65
FIGURE 20 GLOBAL PATENT PUBLICATION TRENDS (JANUARY 2014–DECEMBER 2025) 75
FIGURE 21 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR PREFILLED SYRINGE PATENTS (JANUARY 2014−NOVEMBER 2025) 76
FIGURE 22 TOP APPLICANT COUNTRIES/REGIONS PATENTS FOR PREFILLED SYRINGES (JANUARY 2014−NOVEMBER 2025) 76
FIGURE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR
PREFILLED SYRINGES 86
FIGURE 24 KEY BUYING CRITERIA FOR PREFILLED SYRINGES, BY TYPE 87
FIGURE 25 PREFILLED SYRINGES MARKET: GEOGRAPHIC SNAPSHOT 125
FIGURE 26 NORTH AMERICA: PREFILLED SYRINGES MARKET SNAPSHOT 127
FIGURE 27 ASIA PACIFIC: PREFILLED SYRINGES MARKET SNAPSHOT 153
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN PREFILLED SYRINGES MARKET,
2020–2024 (USD MILLION) 191
FIGURE 29 PREFILLED SYRINGES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2024 192
FIGURE 30 PREFILLED SYRINGES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 195

FIGURE 31 PREFILLED SYRINGES MARKET: COMPANY FOOTPRINT 196
FIGURE 32 PREFILLED SYRINGES MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2025 203
FIGURE 33 BRAND/PRODUCT COMPARATIVE ANALYSIS IN PREFILLED SYRINGES MARKET 205
FIGURE 34 EV/EBITDA OF KEY VENDORS 206
FIGURE 35 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 206
FIGURE 36 R&D EXPENDITURE OF KEY PLAYERS AS PERCENTAGE OF TOTAL REVENUE,
2022–2024 207
FIGURE 37 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT 213
FIGURE 38 GERRESHEIMER AG: COMPANY SNAPSHOT 220
FIGURE 39 SCHOTT: COMPANY SNAPSHOT 226
FIGURE 40 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT 230
FIGURE 41 APTARGROUP, INC.: COMPANY SNAPSHOT 236
FIGURE 42 NIPRO: COMPANY SNAPSHOT 240
FIGURE 43 BAXTER (SIMTRA BIOPHARMA SOLUTIONS): COMPANY SNAPSHOT 244
FIGURE 44 WEIGAO MEDICAL INTERNATIONAL CO., LTD.: COMPANY SNAPSHOT 249
FIGURE 45 NOVARTIS AG: COMPANY SNAPSHOT 253
FIGURE 46 STEVANATO GROUP: COMPANY SNAPSHOT 256
FIGURE 47 PREFILLED SYRINGES MARKET: RESEARCH DESIGN 274
FIGURE 48 PREFILLED SYRINGES MARKET: KEY DATA FROM SECONDARY SOURCES 275
FIGURE 49 PREFILLED SYRINGES MARKET: PRIMARY SOURCES 276
FIGURE 50 PREFILLED SYRINGES MARKET: KEY DATA FROM PRIMARY SOURCES 277
FIGURE 51 KEY INSIGHTS FROM INDUSTRY PLAYERS IN PREFILLED SYRINGES MARKET 278
FIGURE 52 PREFILLED SYRINGES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
(SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 278
FIGURE 53 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 279
FIGURE 54 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 279
FIGURE 55 SUPPLY-SIDE PREFILLED SYRINGES MARKET SIZE ESTIMATION:
REVENUE SHARE ANALYSIS 280
FIGURE 56 REVENUE SHARE ANALYSIS ILLUSTRATION FOR BECTON, DICKINSON
AND COMPANY (BD) (2025) 281
FIGURE 57 SUPPLY-SIDE PREFILLED SYRINGES MARKET SIZE ESTIMATION (2025) 282
FIGURE 58 PREFILLED SYRINGES MARKET: TOP-DOWN APPROACH 282
FIGURE 59 CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS (2026–2031) 284
FIGURE 60 PREFILLED SYRINGES MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS) 284
FIGURE 61 PREFILLED SYRINGES MARKET: DATA TRIANGULATION METHODOLOGY 285

---

---